128 related articles for article (PubMed ID: 29865869)
1. The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended.
Young MK; Ng SK; Nimmo GR; Cripps AW
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):663-669. PubMed ID: 29865869
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure.
Young MK; Ng SK; Nimmo GR; Cripps AW
Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):641-644. PubMed ID: 32362179
[TBL] [Abstract][Full Text] [Related]
3. The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles.
Young MK
Hum Vaccin Immunother; 2019; 15(9):2060-2065. PubMed ID: 31116633
[TBL] [Abstract][Full Text] [Related]
4. Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany.
Matysiak-Klose D; Santibanez S; Schwerdtfeger C; Koch J; von Bernuth H; Hengel H; Littmann M; Terhardt M; Wicker S; Mankertz A; Heininger U
Vaccine; 2018 Dec; 36(52):7916-7922. PubMed ID: 30478003
[TBL] [Abstract][Full Text] [Related]
5. Rubella antibodies in Australian immunoglobulin products.
Young MK; Bertolini J; Kotharu P; Maher D; Cripps AW
Hum Vaccin Immunother; 2017 Aug; 13(8):1952-1955. PubMed ID: 28604142
[TBL] [Abstract][Full Text] [Related]
6. Do Australian immunoglobulin products meet international measles antibody titer standards?
Young MK; Bertolini J; Kotharu P; Maher D; Cripps AW
Hum Vaccin Immunother; 2017 Mar; 13(3):607-612. PubMed ID: 27763809
[TBL] [Abstract][Full Text] [Related]
7. Estimated protective effectiveness of intramuscular immune serum globulin post-exposure prophylaxis during a measles outbreak in British Columbia, Canada, 2014.
Bigham M; Murti M; Fung C; Hemming F; Loadman S; Stam R; Van Buynder P; Lem M
Vaccine; 2017 May; 35(20):2723-2727. PubMed ID: 28392140
[TBL] [Abstract][Full Text] [Related]
8. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP).
McLean HQ; Fiebelkorn AP; Temte JL; Wallace GS;
MMWR Recomm Rep; 2013 Jun; 62(RR-04):1-34. PubMed ID: 23760231
[TBL] [Abstract][Full Text] [Related]
9. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
Kremer JR; Schneider F; Muller CP
Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of measles and rubella antibodies in pregnant women Haiti, 2012.
Fitter DL; Anselme R; Paluku G; Rey G; Flannery B; Tohme RA; Marston BJ; Griswold M; Boncy J; Vertefeuille JF
Vaccine; 2013 Dec; 32(1):69-73. PubMed ID: 24188751
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the immune status against measles, mumps, and rubella in adult allogeneic hematopoietic stem cell transplantation recipients.
Kawamura K; Yamazaki R; Akahoshi Y; Nakano H; Ugai T; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Hematology; 2015 Mar; 20(2):77-82. PubMed ID: 24992512
[TBL] [Abstract][Full Text] [Related]
12. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
[TBL] [Abstract][Full Text] [Related]
13. Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.
St Sauver JL; Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Hum Immunol; 2005 Jul; 66(7):788-98. PubMed ID: 16112026
[TBL] [Abstract][Full Text] [Related]
14. Serosurvey of measles, mumps and rubella antibodies in Saudi children.
Al-Mazrou YY; Khalil MK; Tischer A; Al-Jeffri MH; Al-Ghamdi YS; Bakhsh MM; Mishkas AA; Elgizouli SA
Saudi Med J; 2005 Oct; 26(10):1551-4. PubMed ID: 16228054
[TBL] [Abstract][Full Text] [Related]
15. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.
Leuridan E; Maertens K; Wautier M; Hutse V; Theeten H
Eur J Pediatr; 2015 Jul; 174(7):925-32. PubMed ID: 25579232
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of IgG antibody against measles, mumps and rubella in bangladeshi children: a pilot study to evaluate the need for integrated vaccination strategy.
Sultana R; Rahman MM; Hassan Z; Hassan MS
Scand J Immunol; 2006 Dec; 64(6):684-9. PubMed ID: 17083626
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults.
Kakoulidou M; Ingelman-Sundberg H; Johansson E; Cagigi A; Farouk SE; Nilsson A; Johansen K
Vaccine; 2013 Jan; 31(4):711-7. PubMed ID: 23174196
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a two-dose measles, mumps, and rubella vaccination schedule in a cohort of college athletes.
Coté TR; Sivertson D; Horan JM; Lindegren ML; Dwyer DM
Public Health Rep; 1993; 108(4):431-5. PubMed ID: 8341775
[TBL] [Abstract][Full Text] [Related]
20. Current efficacy of postexposure prophylaxis against measles with immunoglobulin.
Endo A; Izumi H; Miyashita M; Taniguchi K; Okubo O; Harada K
J Pediatr; 2001 Jun; 138(6):926-8. PubMed ID: 11391343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
